VEGF is a mediator in the pathogenesis of certain eye conditions, including wet age-related macular degeneration (AMD), diabetic retinopathy and macular oedema secondary to retinal vein occlusions.

faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and Efficiency in ...

Diabetic macular edema can result in low vision or ... When fluid gets into the retina’s center part, called the macula, it causes swelling. This can affect vision and, in some cases, lead ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Diabetic retinopathy (DR), a frequent form of diabetic eye illness, damages the retina's blood vessels and can result in additional dangerous disorders such as diabetic macular oedema (DME).

Further information Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294).